Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Charles Schwab Corporation Common Stock trades at $103.5 (market cap $179.34B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SCHW | |
|---|---|---|
Market Cap | $39.89B | $179.34B |
Sector | Health | Financials |
52-Week High | $491.22 | $107.21 |
52-Week Low | $278.09 | $85.35 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Charles Schwab (SCHW) trades at $103.12, up 1.19% today, near its pivot point of $102 with bullish technical momentum. The stock shows strong fundamentals with a 37.99% net income margin and 21.79% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights a Zacks upgrade to Strong Buy and a four-year high in the Schwab Trading Activity Index, reflecting robust retail engagement.
Outlook remains positive with a consensus price target of $122.71 implying 19% upside, though overbought RSI signals near-term caution. Risks include interest rate sensitivity and competitive pressures, but institutional bullishness and expanding prediction market initiatives offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
